NCT04431440

Brief Summary

Recently, silver nanoparticles (AgNPs) have been widely used in various applications as antimicrobial agents, anticancer, diagnostics, biomarkers, cell labels, and drug delivery systems for the treatment of various diseases. The present study investigated the bactericidal effect of AgNPs against Methecillin Resistant Staph. aureus (MRSA) and Vancomycin resistant Staph aureus (VRSA)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2020

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

June 11, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 5, 2020

Completed
8 days until next milestone

Study Completion

Last participant's last visit for all outcomes

October 13, 2020

Completed
Last Updated

November 5, 2020

Status Verified

November 1, 2020

Enrollment Period

4 months

First QC Date

June 11, 2020

Last Update Submit

November 4, 2020

Conditions

Multidrug Resistent Bacteria

Outcome Measures

Primary Outcomes (1)

  • bactericidal effect of silver nanoparticles on multidrug resistant bacteria

    24 hours

Study Arms (2)

Methicillin resistant staphylococcus aureus

Other: silver nanoparticles

vancomycin resistent staphylococcus aureus

Other: silver nanoparticles

Interventions

silver nanoparticlesOTHER

effect silver nanoparticles will be examined on multidrug resistant bacteria

Methicillin resistant staphylococcus aureusvancomycin resistent staphylococcus aureus

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

critically ill patients

You may qualify if:

  • Intensive care patients

You may not qualify if:

  • none

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut university

Asyut, 71111, Egypt

Location

Related Publications (1)

  • Elsawy S, Elsherif WM, Hamed R. Effect of silver nanoparticles on vancomycin resistant Staphylococcus aureus infection in critically ill patients. Pathog Glob Health. 2021 Jul;115(5):315-324. doi: 10.1080/20477724.2021.1914412. Epub 2021 Apr 19.

    PMID: 33872131DERIVED

MeSH Terms

Interventions

colloidal silver

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anaesthesia

Study Record Dates

First Submitted

June 11, 2020

First Posted

June 16, 2020

Study Start

June 1, 2020

Primary Completion

October 5, 2020

Study Completion

October 13, 2020

Last Updated

November 5, 2020

Record last verified: 2020-11

Locations

EG(1)